Andrea Necchi, MD

Andrea Necchi, MD, is an associate professor at Vita-Salute Raffaele University and the head of genitourinary medical oncology at IRCCS San Raffaele Hospital and Scientific Institute in Italy.

Articles

Oncology Experts Dive Into Top Data From ESMO 2025

November 4th 2025

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Dr Necchi on Biomarker Data From the SunRISe-4 Trial of Gemcitabine Intravesical System Plus Cetrelimab in MIBC

October 17th 2025

Andrea Necchi, MD, discusses the role of minimal residual disease assessment in the phase 2 SunRISe-4 trial evaluating TAR-200 plus cetrelimab in MIBC.

Dr Necchi on the Design of the Phase 2 SURE-02 Study Assessing Pembrolizumab/Sacituzumab Govitecan in Muscle-Invasive Bladder Cancer

September 10th 2025

Andrea Necchi, MD, discusses the design of the SURE-02 study evaluating pembrolizumab plus sacituzumab govitecan in muscle-invasive bladder cancer.

Dr Necchi on Molecular Data With Perioperative Sacituzumab Govitecan Plus Pembrolizumab in MIBC

August 28th 2025

Andrea Necchi, MD, discusses biomarker data with perioperative sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible MIBC.

Dr Necchi on Responses With TAR-200 According to PD-L1 Status in NMIBC

September 27th 2024

Andrea Necchi, MD, discusses treatment with TAR-200 by PD-L1 expression in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer with CIS.

Dr Necchi on the Efficacy and Safety of TAR-200 Plus Cetrelimab in MIBC

September 26th 2024

Andrea Necchi, MD, discusses an analysis of the SunRise-4 trial evaluating TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer.

Dr Necchi on the Efficacy of TAR-200 Monotherapy in BCG-Unresponsive NMIBC

January 4th 2024

Andrea Necchi, MD, discusses results from the phase 2b SunRISe-1 trial of TAR-200 in patients with Bacillus Calmette-Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer.

Dr. Necchi on Key Results From Cohort B of the KEYNOTE-057 Trial in MIBC

February 17th 2023

Andrea Necchi, MD, discusses updated analysis of cohort B in the phase 2 KEYNOTE-057 trial in non-muscle invasive bladder cancer.

Dr. Necchi on Impact of PD-1 Inhibition in Bladder Cancer

November 17th 2017

Andrea Necchi, MD, a medical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, discusses the impact of PD-1 inhibition in bladder cancer as well as the promise with combination strategies.